The human body is more than the sum of its organs. Yet for hundreds of years, medicine and medical research have divvied up the totality of the person into diseases that are organ specific and characterized largely by their phenotypic presentation. These divisions are also reflected in the organization of academic medical centers and pharmaceutical research and development and even permeate the funding of biomedical research, with diseasecentered NIH institutes and private foundations. This is understandable, and I am not suggesting that it should be eliminated because it is still a critical structure for delivering patient care. But in research, our understanding of the functioning of the body and the causes of disease has progressed beyond the phenotypic, and I would argue that the present structure has led to the curtaining off of one organ or disease from its brethren. An individual is the sum of their medical history, and having one disease can greatly alter the likelihood of having another. We know now that chronic inflammation also increases cancer risk (e.g., ulcerative colitis and colorectal cancer) and is also a risk factor for obesity and neurodegeneration. These comorbidities can be explained in terms of common cellular and molecular pathways. We need to think of new ways to organize research into hubs informed by common themes-for example, the aging process or genetic medicine-where physician scientists and basic researchers from different traditional disciplines can come together. In this way, we can begin to see behind the curtain that divides one branch of knowledge from another.
Progress through Partnership

Olle Lindvall
University Hospital, Lund Despite remarkable achievements in basic neuroscience, effective therapies are still lacking for many neurological disorders, such as stroke, Alzheimer's disease, and spinal cord injury. Strong curiosity-driven basic research remains fundamental for clinical advancements. However, for basic research to have a greater impact on clinical challenges, clinicians must be involved from an earlier stage and not just immediately prior to application in patients.
Basic scientists should be educated in the clinical features of neurological disease and the problems related to diagnosis and therapy. Better animal models that reflect the complex pathology and pathogenesis of neurological disease have to be developed in collaboration with clinicians. Many current models use otherwise healthy, young animals, which is far from the clinical situation in which patients are often older, with concurrent diseases and chronic medication.
Basic scientists and clinicians together have to develop functional and behavioral tests in animals that assess deficits resembling impairments in patients. The new imaging techniques for monitoring brain and spinal cord in vivo in animals and humans create golden opportunities for interaction between basic scientists and clinicians.
The critical scientific steps from basic research to patient application should be defined in cooperation between basic scientists and clinicians. This partnership must function throughout all stages of clinical translation if basic research findings are to be efficiently converted to novel treatments for neurological disorders.
Do Traits Influence Therapy?
Vince Aguirre
UT Southwestern Medical Center
A rapidly growing number of genetic loci have been linked to characteristic traits. This often leaves clinicians wondering the meaning for their individual patients. This is especially true when the ability to query a particular locus outpaces understanding of its clinical implications. Transgenic methods of gene activation, deletion, and substitution in cells and lower organisms enable relatively quick assessment of the functional consequences of genetic variability at a particular locus. These data shed light on underlying mechanism and guide the astute clinical investigator in the early uses of new genetic diagnostics. This approach is particularly useful when it would take much time (often years) to collect the number of patients necessary to rigorously address an important clinical question. An example is the scenario currently facing the bariatric community. Multiple loci have been convincingly associated with obesity. The question posed is this: do variants that predispose to obesity also result in resistance to therapy? While not necessarily important for most pharmaceuticals, which are safe and easily reversible, this question is relevant in particular for surgical interventions, which carry a higher risk of morbidity and mortality. Basic research can provide novel biological insights regarding both disease susceptibility and therapeutic resistance and therefore will greatly impact the practice of medicine in the future, especially as the library of susceptibility loci continues to grow. To paraphrase a well-known Nobel laureate, ''There are a lot of people studying cancer, but maybe we could cure cancer if we would just do it.'' Factors initiating and driving human tumors are infinitely more complex than imagined when the war on cancer was declared decades ago. The naively brash enthusiasm for a rapid conquest in the 1970s and 1980s has been replaced by steady determination, strategic scientific advances, and a growing number of victories that will eventually win the war. The definition of ''winning the war'' has also evolved over the years, from complete and permanent cures for all cancer patients to re-establishing a durable symptom-free state of equilibrium. In confronting the diversity and mutability of human cancers, basic scientists and translational oncologists can perhaps have the greatest clinical impact by discovering vital tumor-associated molecules or pathways for targeted drug development and by defining biomarkers predictive of clinical response. These goals are often approached from a genetic vantage point, and clinical results such as those from targeting mutant BRAF in melanoma or BCR/ABL in CML provide strong proof of principle. However, specific targets relevant to cancer immunology, metabolism, and epigenetics are equally as important although somewhat more difficult to conceptualize and validate. It is rapidly becoming appreciated that rational synergistic combination therapies supported by strong basic science, rather than monotherapies, will be needed to achieve our goals.
GWAS Follow Up for CVD
Kiran Musunuru
Harvard University Cardiovascular disease is the number one killer worldwide. We have very few medications that have been proven to reduce the risk of cardiovascular disease, in part because the pathogenetic mechanisms still remain to be fully determined. Epidemiological work done half a century ago led to recognition of the ''traditional'' risk factors for disease-high cholesterol, hypertension, diabetes, tobacco use, etc. Preventive cardiology has largely focused on managing these risk factors with therapeutic lifestyle changes and, when warranted, medications. But despite our best efforts, millions of patients still develop disease.
The Human Genome Project has led to the development of powerful new genetic techniques such as genome-wide association mapping and whole-exome sequencing. The application of these unbiased techniques to patients with cardiovascular disease is now illuminating novel risk factors about which we had no previous knowledge-the most prominent example being a genetic locus on chromosome 9p21, which remains a mystery.
Basic research is sorely needed to undertake the difficult work of determining the molecular mechanisms that underlie these novel risk factors. The hope is that, as we gain a better understanding of these mechanisms, we will be able to craft therapies that target the novel risk factors and thereby complement existing medications, with the goal of sharply reducing the number of people suffering and dying from cardiovascular disease. Combination antiretroviral therapy (cART) has transformed HIV/AIDS from an almost invariably fatal disease to one that can be successfully managed for decades. However, it is extremely unlikely that we will have the financial or operational capacity to provide a lifetime of cART to everyone who requires it, especially as 7,000 new infections occur daily. In addition, patients receiving long-term cART can experience drug toxicities, drug resistance, and even treatment failures. Therefore, the imperative to develop a cure for HIV looms large. In this case, cure is defined as the lack of virus replication in the absence of therapy. The basic research with the greatest potential impact involves finding innovative approaches to eradicate or permanently suppress the virus, thereby eliminating the need for lifelong antiretroviral therapy. The impact of a cure would be profound for individuals and society. Patients would be spared the cumulative effects of drug toxicities; they would almost certainly not transmit the virus to others; and the considerable resources spent on cART would be freed up for other services. In this regard, an intensive basic research effort is underway to delineate the precise mechanisms whereby HIV persists despite effective therapy. Such information will be used to develop novel interventions to eliminate or permanently suppress the recalcitrant reservoirs of HIV not eliminated with current therapies. A cure for HIV would be truly transformative.
